As Biotechnology businesses, Sutro Biopharma Inc. (NASDAQ:STRO) and TG Therapeutics Inc. (NASDAQ:TGTX), are affected by compare. This especially applies to their risk, analyst recommendations, profitability, institutional ownership, dividends, earnings and valuation.
Earnings and Valuation
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Sutro Biopharma Inc.||11||6.41||N/A||-1.58||0.00|
|TG Therapeutics Inc.||7||4710.67||N/A||-2.30||0.00|
Table 1 shows gross revenue, earnings per share and valuation of the two companies.
Table 2 shows Sutro Biopharma Inc. and TG Therapeutics Inc.’s return on equity, net margins and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Sutro Biopharma Inc.||0.00%||0%||0%|
|TG Therapeutics Inc.||0.00%||-213.2%||-130.9%|
The current Quick Ratio of Sutro Biopharma Inc. is 5.8 while its Current Ratio is 5.8. Meanwhile, TG Therapeutics Inc. has a Current Ratio of 2 while its Quick Ratio is 2. Sutro Biopharma Inc. is better positioned to pay off its short-term and long-term debts than TG Therapeutics Inc.
Recommendations and Ratings for Sutro Biopharma Inc. and TG Therapeutics Inc. can be find in next table.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|Sutro Biopharma Inc.||0||0||0||0.00|
|TG Therapeutics Inc.||0||0||2||3.00|
Meanwhile, TG Therapeutics Inc.’s average price target is $17.5, while its potential upside is 119.85%.
Insider and Institutional Ownership
Roughly 71.6% of Sutro Biopharma Inc. shares are owned by institutional investors while 67.5% of TG Therapeutics Inc. are owned by institutional investors. Insiders owned roughly 21.23% of Sutro Biopharma Inc.’s shares. On the other hand, insiders owned about 0.5% of TG Therapeutics Inc.’s shares.
In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Sutro Biopharma Inc.||-2.4%||-13.91%||-2.4%||-24.31%||0%||12.53%|
|TG Therapeutics Inc.||-14.18%||-11.25%||52.61%||26.71%||-49.13%||71.22%|
For the past year Sutro Biopharma Inc.’s stock price has smaller growth than TG Therapeutics Inc.
On 5 of the 8 factors Sutro Biopharma Inc. beats TG Therapeutics Inc.
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis platform, XpressCF. The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for multiple myeloma and non-Hodgkin lymphoma; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers. It has collaboration and license agreement with Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused primarily on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
TG Therapeutics, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases primarily in the United States. It develops TG-1101 (ublituximab), a chimeric, glycoengineered monoclonal antibody that targets an epitope on the CD20 antigen found on the surface of B-lymphocytes developed to aid in the depletion of circulating B-cells; and TG-1101 in combination with TGR-1202 for relapsed/refractory non-HodgkinÂ’s lymphoma and chronic lymphocytic leukemia. The company also develops TGR-1202, an orally available phosphoinositide-3-kinase delta inhibitor with nanomolar potency to the delta isoform and high selectivity over the alpha, beta, and gamma isoforms, as well as for hematologic malignancies. In addition, it develops a pre-clinical program to develop interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors; bromodomain and extra terminal (BET) inhibitor program in the field of hematological malignancies; and anti-PD-L1 and anti-GITR antibody research programs that are in pre-clinical development stage in the field of hematological malignancies. The company has license agreements with LFB Biotechnologies S.A.S, GTC Biotherapeutics, LFB/GTC LLC, and Ildong Pharmaceutical Co. Ltd. for the development and commercialization of TG-1101 (ublituximab); Rhizen Pharmaceuticals, SA for the development and commercialization of TGR-1202; Ligand Pharmaceuticals Incorporated for the development and commercialization of IRAK4 inhibitor technology; Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs; and Jubilant Biosys for the development and commercialization of BET inhibitor program. TG Therapeutics, Inc. is headquartered in New York, New York.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.